한글목차

클로비스 종양가 개발한 RUBRACA(루카파립)는 경구용 저분자 PARP1, PARP2, PARP3 억제제로 난소암, 전이성 거세저항성 전립선암 등 여러 암종을 대상으로 단독요법 및 다른 항암제와의 병용요법으로 개발되고 있습니다. 또한, 다른 종양 유형에 대한 탐색 연구도 진행 중입니다.

백금 기반 화학요법에 완전 또는 부분 반응을 보인 재발성 상피성 난소암, 난관암, 원발성 복막암 성인 여성의 유지요법, BRCA 유전자 변이(생식세포계 및/또는 체세포계)가 있는 상피성 난소암, 난관암, 원발성 복막암의 유지요법, 그리고 두 가지 이상의 항암화학요법을 받은 성인 여성의 치료에 적응증을 가지고 있습니다.

앞으로 몇 년동안 난소암 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 증가로 인해 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 도전과제를 평가하고, 루브라카의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 난소암을 대상으로 하는 다른 신약들이 루브라카와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 난소암 치료제 RUBRACA 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 난소암 치료제 RUBRACA 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 RUBRACA 시장 평가

• 난소암 치료제 RUBRACA 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 난소암 치료제 RUBRACA 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"RUBRACA Market Size, Forecast, and Drug Insight - 2032" report provides comprehensive insights about RUBRACA for ovarian cancer in the seven major markets. A detailed picture of the RUBRACA for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the RUBRACA for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RUBRACA market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

RUBRACA (Rucaparib), developed by Clovis Oncology, is an oral, small-molecule inhibitor of PARP1, PARP2, and PARP3, developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anticancer agents. Exploratory studies on other tumor types are also underway.

RUBRACA is approved by US FDA for the following patient segments:-

• It is indicated for the maintenance treatment of adult women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
• It is indicated for the treatment of adult women with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the RUBRACA description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on RUBRACA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the RUBRACA research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around RUBRACA.
• The report contains forecasted sales of RUBRACA for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for RUBRACA in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RUBRACA Analytical Perspective by DelveInsight

• In-depth RUBRACA Market Assessment

This report provides a detailed market assessment of RUBRACA for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• RUBRACA Clinical Assessment

The report provides the clinical trials information of RUBRACA for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RUBRACA dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to RUBRACA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RUBRACA in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of RUBRACA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RUBRACA in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of RUBRACA?
• What is the clinical trial status of the study related to RUBRACA in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RUBRACA development?
• What are the key designations that have been granted to RUBRACA for ovarian cancer?
• What is the forecasted market scenario of RUBRACA for ovarian cancer?
• What are the forecasted sales of RUBRACA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to RUBRACA for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. RUBRACA Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. RUBRACA Market Assessment

• 5.1. Market Outlook of RUBRACA in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of RUBRACA in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of RUBRACA in the United States for ovarian cancer
  • 5.3.2. Market Size of RUBRACA in Germany for ovarian cancer
  • 5.3.3. Market Size of RUBRACA in France for ovarian cancer
  • 5.3.4. Market Size of RUBRACA in Italy for ovarian cancer
  • 5.3.5. Market Size of RUBRACA in Spain for ovarian cancer
  • 5.3.6. Market Size of RUBRACA in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of RUBRACA in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options